| Company/Division name | Kite Pharma |
| Parent company | Gilead Sciences, Inc. |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 400 |
| What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
| Year reshoring announced: | 2022 |
| Year reshoring implemented or to be implemented: | 2022 |
| Domestically, the work will be done: | In-house |
| City reshored to: | Frederick |
| State(s) reshored to: | MD |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | CAR T-cell therapy |
| What domestic positive factors made reshoring more attractive? | Skilled workforce availability/training |
